[ABSTRACT]AIM:Toobservetheeffectsofpuerarincombinedwithsaxagliptinonrenalfibrosisintype2dia-betic rats.METHODS:Fifty male Wistar rats were used, of which 8 rats were randomly chosen as normal control group , and the remaining rats were used to establish the type 2 diabetic model.The rats that met the criterion for the diabetic mo-del were randomly divided into model group , puerarin treatment group , saxagliptin treatment group , puerarin combined with saxagliptin treatment group and metformin combined with saxagliptin treatment group .The above-mentioned drugs were ad-ministered for 8 weeks.After that period, all rats were sacrificed.The kidney index (kidney weight/body weight),and blood glucose and HbA1c were examined in all the rats.The morphological changes were observed by HE and Masson stai-ning.The levels of TNF-αand macrophage migration inhibitory factor (MIF) in the serum were measured by ELISA .The mRNA expression of TNF-α, MIF and CD68 was examined by RT-PCR.RESULTS: Compared with normal group , the kidney index, blood glucose and HbA1c, the levels of TNF-αand MIF in the serum and the mRNA expression of TNF-α, MIF and CD68 were increased (P<0.05) in the kidney tissues of model group .Compared with model group , the kidney index, blood glucose and HbA1c, the levels of MIF and TNF-αin the serum and the mRNA expression of TNF-α, MIF and CD68 were decreased ( P<0.05) in puerarin combined with saxagliptin treatment group .CONCLUSION:Puerarin com-bined with saxagliptin reduces blood glucose , decreases MIF and TNF-α, and down-regulates the mRNA expression of TNF-α, MIF and CD68 in the kidney tissues of type 2 diabetic rats, which may contribute to the inhibition of renal fibrosis .%目的：观察葛根素联用沙格列汀对2型糖尿病大鼠肾脏纤维化的影响。方法：Wistar大鼠50只，雄性，随机抽取8只作为正常对照组，其余复制2型糖尿病大鼠模型。将造模成功的大鼠随机分为糖尿病对照组、葛根素治疗组、沙格列汀治疗组、葛根素联用沙格列汀治疗组和二甲双胍联用沙格列汀治疗组。各治疗组给予相应药物治疗，2个对照组腹腔注射相应量的生理盐水。第8周后，测定各组大鼠肾重指数（肾重/体重）、血糖和糖化血红蛋白含量等；电子显微镜观察肾组织病理变化；ELISA法检测血清中炎症因子肿瘤坏死因子α（ TNF-α）和巨噬细胞移动抑制因子（ MIF）含量；RT-PCR法检测大鼠肾组织TNF-α、MIF和巨噬细胞标记物CD68 mRNA表达。结果：糖尿病对照组与正常组相比，大鼠肾重指数、血糖与糖化血红蛋白上升（P＜0．01或P＜0．05），血清中TNF-α及MIF含量明显上升（P＜0．01），肾脏组织中TNF-α、MIF及CD68 mRNA表达上升（P＜0．05）；与糖尿病对照组比较，葛根素联用沙格列汀治疗组的肾重指数、血糖及糖化血红蛋白下降（P＜0．01或P＜0．05），血清中TNF-α及MIF含量下降（P＜0．05），肾脏组织中的TNF-α、MIF及CD68 mRNA表达下降（P＜0．05）；与单用药组比较，联用组在各指标改善程度上更显著。结论：葛根素联用沙格列汀能降低血糖和血清中TNF-α、MIF含量，下调TNF-α、MIF及CD68 mRNA在大鼠肾脏组织的表达。糖尿病大鼠肾脏纤维化被抑制的机制可能与上述指标的变化有关。
展开▼
